THERAPEUTIC AGENT FOR SYSTEMIC BONE DISEASE AND USE THEREOF

摘要

The object is to provide a novel therapeutic strategy achieving high therapeutic effect on a skeletal dysplasia caused by excessive activation of FGFR3, particularly achondroplasia and hypochondroplasia. Provided is a therapeutic agent for a skeletal dysplasia, including meclizine or its pharmaceutically acceptable salt as an active ingredient.

主权项

1. A therapeutic agent for a skeletal dysplasia caused by excessive activation of fibroblast growth factor receptor 3 (FGFR3), the therapeutic agent comprising meclizine or its pharmaceutically acceptable salt as an active ingredient.